# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $5 price target.
Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $...